PLx Pharma Winddown Corp.

OTCPK:PLXP.Q Voorraadrapport

Marktkapitalisatie: US$30.0

PLx Pharma Winddown Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

PLx Pharma Winddown has a total shareholder equity of $26.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $33.2M and $6.9M respectively.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$25.83m
AandelenUS$26.33m
Totaal verplichtingenUS$6.89m
Totaal activaUS$33.22m

Recente financiële gezondheidsupdates

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

May 10
Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Sep 23
We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Jun 15
PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Recent updates

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

Aug 12

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

May 10
Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Nov 03
Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Sep 23
We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

PLx Pharma: First Commercial Launch Makes It Attractive

Sep 17

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Jun 15
PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?

Mar 05
Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?

PLx Pharma EPS misses by $0.10

Nov 16

Analyse van de financiële positie

Kortlopende schulden: PLXP.Q's short term assets ($30.2M) exceed its short term liabilities ($6.3M).

Langlopende schulden: PLXP.Q's short term assets ($30.2M) exceed its long term liabilities ($582.0K).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PLXP.Q is debt free.

Schuld verminderen: PLXP.Q has no debt compared to 5 years ago when its debt to equity ratio was 56.2%.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Insufficient data to determine if PLXP.Q has enough cash runway based on its current free cash flow.

Voorspelling contante baan: Insufficient data to determine if PLXP.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Ontdek gezonde bedrijven